Previous 10 | Next 10 |
– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML – – Low frequency of differentiation syndrome, including 5% rate (1/20) of ≥ Grade 3 among NPM1-mutant patients treated at 600 mg – – 600 mg determined as recommended Phas...
SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will host an investor event featuring members of the Kura mana...
Summary Today, we look back in on small cap developmental concern Kura Oncology for the first time in two years. Last week, the company reported third quarter results and got a $25 million equity investment from drug giant Bristol Myers Squibb. An investment analysis follows i...
Kura Oncology, Inc. (KURA) Q3 2022 Earnings Conference Call November 3, 2022 8:00 am ET Corporate Participants Pete De Spain - Senior Vice President of Investor Relations Troy Wilson - President and Chief Executive Officer Tom Doyle - Senior Vice President of Fin...
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that four abstracts highlighting ziftomenib, the Company’...
Kura Oncology press release ( NASDAQ: KURA ): Q3 GAAP EPS of -$0.53 beats by $0.03 . Net loss for the third quarter of 2022 was $35.5 million, compared to a net loss of $33.4 million for the third quarter of 2021. Shares -1.4% PM. For further details see:...
– Abstract reporting updated data from KOMET-001 accepted for oral presentation at ASH – – First demonstration of durable clinical response with tipifarnib plus alpelisib in HNSCC – – AIM-HN trial of tipifarnib in HRAS mutant HNSCC closed to furt...
– $25 million equity investment from Bristol Myers Squibb at $18.25 per share – – Term loan facility from Hercules Capital provides up to $125 million – – Proceeds extend Kura’s cash runway into 2026, if term loan is fully drawn ...
Kura Oncology ( NASDAQ: KURA ) is scheduled to announce Q3 earnings results on Thursday, November 3rd, before market open. The consensus EPS Estimate is -$0.56 Over the last 3 months, EPS estimates have seen 2 upward revisions and 6 downward. For further deta...
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2022 financial results before ...
News, Short Squeeze, Breakout and More Instantly...
2024-05-25 10:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-23 17:00:08 ET Bradley Canino from Stifel Nicolaus issued a price target of $28.00 for KURA on 2024-05-23 16:03:00. The adjusted price target was set to $28.00. At the time of the announcement, KURA was trading at $21.43. The overall price target consensus is at ...
– Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months – – Topline data expected in early 2025 – – Breakthrough Therapy Designation to enable expedited review by FDA – SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- ...